[
    [
        {
            "time": "",
            "original_text": "健帆生物：拟投资建设血液净化项目 完善公司华南、华中、华北产业战略布局",
            "features": {
                "keywords": [
                    "健帆生物",
                    "血液净化",
                    "投资项目",
                    "产业布局"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "健帆生物：拟投资建设血液净化项目 完善公司华南、华中、华北产业战略布局",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "健帆生物：拟在珠海投资约15亿元建医疗器械（血液净化）项目",
            "features": {
                "keywords": [
                    "健帆生物",
                    "珠海",
                    "医疗器械",
                    "血液净化",
                    "投资项目"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "健帆生物：拟在珠海投资约15亿元建医疗器械（血液净化）项目",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【健帆生物】【安信医药马帅团队】年报详尽点评：19年业绩符合预期，血液净化业务不断拓展",
            "features": {
                "keywords": [
                    "健帆生物",
                    "年报",
                    "业绩",
                    "血液净化",
                    "业务拓展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【健帆生物】【安信医药马帅团队】年报详尽点评：19年业绩符合预期，血液净化业务不断拓展",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]